GeneDx logo

Disease should be rare. Diagnosis shouldn’t.

That’s the future we’re building at GeneDx.

Comprehensive genomic insights. Precision medicine. Improved outcomes.

We deliver personalized and actionable health insights that inform diagnosis, direct treatment, and improve drug discovery

Are you a healthcare provider?

Discover how genetic testing could benefit your practice and your patients.

Learn more

Are you a patient or caregiver?

Find answers to your genetic testing questions.

Learn more

Help your patients reach a genetic diagnosis faster with genome and exome testing

We’re moving exome and genome from specialized tests to the standard of care, improving patients’ lives by building a future where we can sequence DNA once and analyze the results for a lifetime.

Graphic of ~2-3x

Whole exome sequencing (WES) can deliver ~2-3x the diagnostic yield of chromosomal microarray (CMA) and multigene panels1-4

Discover exome sequencing

Graphic of 1 in 3

1 in 3 babies in the NICU is likely to have a genetic condition that could be diagnosed with rapid whole genome sequencing5

Discover genome sequencing

Graphic for Patients

More actionable results.
More effective treatment plans.

We leverage our extensive database and proprietary interpretation services to analyze genetic information, enabling a greater chance of a genetic diagnosis. These comprehensive and personalized insights can help inform healthcare decisions and connect patients with crucial resources.

Explore our offerings

With comprehensive care from start to finish, we offer more than just a test result

  • We’re a leader in genomics. We’ve interpreted and delivered over 500,000 clinical exome and genome tests allowing us to offer premier exome sequencing expertise for pediatric conditions and rare and ultra-rare genetic diseases, while enabling precision medicine as the standard of care.
  • We deliver better health insights. Centrellis®, our proprietary health intelligence platform, integrates digital tools with artificial intelligence to ingest and synthesize clinical and genomic data.
  • We back our science with support. Our dedicated team of genetic counselors provides peer-to-peer support as well as pre-and post-test counseling services.
Learn more about GeneDx

In the news

September 22, 2023

GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GeneDx, a leader in delivering improved health outcomes through genomic and clinical insights, today announced that, effective as of October 1, the compensation committee of GeneDx’s board of directors granted newly-hired employees 133,998 restricted stock units (“RSUs”) as inducements material to each employee entering into employment with GeneDx.

September 11, 2023

GeneDx Announces Evolution of Executive Leadership Team

Melanie Duquette joining team as Chief Growth Officer to drive commercial excellence, Jennifer Brendel to take new role as Chief of Corporate Affairs amplifying the GeneDx brand and leadership platform.

September 6, 2023

GeneDx Announces Industry-Leading Accomplishment of 500,000 Clinical Exomes Sequenced

GeneDx, a leader in delivering improved health outcomes through genomic and clinical insights, today announced a monumental accomplishment in its ongoing commitment to deliver personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery.